An evaluation of pharmaceutical treatment of dyslipidaemia among patients without diagnosed atherosclerotic disease in Belgium.
The aim of this study was to assess the lipoprotein levels in patients without diagnosed atherosclerotic disease but treated with lipid-lowering drugs. During February and March 2002 all demands for continuation of reimbursement of lipid-lowering drugs were recorded at two regional offices of health insurance associations. A total of 1973 patients without diagnosed atherosclerotic disease were included (mean age 66 years). Mean total cholesterol (TC) was 5.39 mmol/l, high-density lipoprotein cholesterol (HDL-C) 1.50 mmol/l, low-density lipoprotein cholesterol (LDL-C) 3.16 mmol/l and triglycerides (TG) 1.59 mmol/l. Thirty-four per cent of the treated patients reached the TC target of 5.0 mmol/l or less. The LDL-C target level of 3.0 mmol/l or less was reached by 45% of the patients. Of the patients receiving a statin, 61% were not treated with the optimal doses. The treatment was adjusted in 15% of the patients who did not reach the combined endpoint.